



STIC Search Report

6w14

Biotech-Chem Library

STIC Database Tracking Number: 180090

TO: Michael Borin
Location: REM/2A55/2C70
Art Unit: 1631
Monday, February 27, 2006

Case Serial Number: 10/825661

From: Mary Hale
Location: Biotech/Chem Library
Rem 1D86
Phone: 2-2507

Mary.Hale@uspto.gov

Search Notes

Feel free to contact me if you have any questions.

Note -- results are printed on both sides of printout

140

ACCESS DB # 180090
PLEASE PRINT CLEARLY

FOR OFFICIAL USE ONLY

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: Michael BORIN Examiner #: 74104 Date: 02/21/06
Art Unit: 1631 Phone Number: 2-0713 Serial Number: 10/825661
Location (Bldg/Room#): 2A55 (Mailbox #): 2 Results Format Preferred (circle): PAPER DISK

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: _____

Inventors (please provide full names): _____

Earliest Priority Date: _____

Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please 1) search claims 21, 22.
2) Inventor search

Peter Pang
Jacqueline Shan
Kam Chiu

Thank you

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-20 (Canceled)

21. (New) A shark cartilage extract with anti-PHF activity, wherein the shark cartilage extract is produced by the following steps:

extracting cleaned, dried, ground shark cartilage with H₂O at a temperature between 85-120°C for 2-4 hours,

centrifuging the resulting suspension 1 at between 5200 to 5700 rpm to separate the suspension into supernatant 1 and pellet,

holding the supernatant 1 in a cooling tank 4-8°C,

extracting the pellet a second time with H₂O at a temperature between 85-120°C for 2-4 hours,

centrifuging the resulting suspension 2 at between 5200-5700 rpm to separate the suspension into supernatant 2 and pellet;

pooling supernatant 1 with supernatant 2, and

lyophilizing the pooled supernatants to obtain the shark cartilage extract.

22. (New) The shark cartilage extract according to claim 21, further comprising cooling said suspension 1 and suspension 2 to between 40-60°C when said suspensions are at a temperature greater than 60°C.

neovastat
AE-941

chondrichthyes
cartilaginous fish

antagonist
of anti parathyroid hypertensive factor

Boun
10/825661

Page 1

=> fil medl,biosis,embase,caplus,wpids
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
5.96	10.91

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 14:35:33 ON 27 FEB 2006

FILE 'BIOSIS' ENTERED AT 14:35:33 ON 27 FEB 2006

Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 14:35:33 ON 27 FEB 2006

Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 14:35:33 ON 27 FEB 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 14:35:33 ON 27 FEB 2006

COPYRIGHT (C) 2006 THE THOMSON CORPORATION

=> s l2 or shark cartilage ext?

L3	43 FILE MEDLINE
L4	36 FILE BIOSIS
L5	25 FILE EMBASE
L6	34 FILE CAPLUS
L7	23 FILE WPIDS

TOTAL FOR ALL FILES

L8 161 L2 OR SHARK CARTILAGE EXT?

=> s l8 and anti phf

L9	0 FILE MEDLINE
L10	0 FILE BIOSIS
L11	0 FILE EMBASE
L12	0 FILE CAPLUS
L13	0 FILE WPIDS

TOTAL FOR ALL FILES

L14 0 L8 AND ANTI PHF

=> s phf and l8

L15	0 FILE MEDLINE
L16	0 FILE BIOSIS
L17	0 FILE EMBASE
L18	1 FILE CAPLUS
L19	1 FILE WPIDS

TOTAL FOR ALL FILES

L20 2 PHF AND L8

=> dup rem l20

PROCESSING COMPLETED FOR L20

L21 1 DUP REM L20 (1 DUPLICATE REMOVED)

=> d ibib abs

L21 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 1999:64822 CAPLUS

DOCUMENT NUMBER: 130:90515

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

TITLE: A preparation derived from shark cartilage for treatment of diseases related to excessive parathyroid hypertensive factor or excessive intracellular calcium

INVENTOR(S): Pang, Peter K. T.; Shan, Jacqueline J.; Chiu, Kam W.

PATENT ASSIGNEE(S): CV Technologies Inc., Can.

SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9902548	A1	19990121	WO 1998-US13591	19980709
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2295519	AA	19990121	CA 1998-2295519	19980709
AU 9883790	A1	19990208	AU 1998-83790	19980709
EP 1012163	A1	20000628	EP 1998-934212	19980709
R: AT, CH, DE, FR, GB, LI, FI				
JP 2001509513	T2	20010724	JP 2000-502067	19980709
US 2004234617	A1	20041125	US 2004-825661	20040416
PRIORITY APPLN. INFO.:				
			US 1997-52233P	P 19970711
			WO 1998-US13591	W 19980709
			US 2000-462094	A1 20000111

AB **Shark cartilage extract** has been shown to be an antagonist of parathyroid hypertensive factor (PHF). In view of this, **shark cartilage extract** can be used to treat conditions related to excessive PHF activity. Such diseases include hypertension and some other diseases related to intracellular calcium elevation. Methods for producing the **shark cartilage extract** and methods for administering the extract are disclosed.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s pang p?/au;s shan j?/au;s chiu k?/au

L22 315 FILE MEDLINE
L23 470 FILE BIOSIS
L24 303 FILE EMBASE
L25 451 FILE CAPLUS
L26 48 FILE WPIDS

TOTAL FOR ALL FILES

L27 1587 PANG P?/AU

L28 200 FILE MEDLINE
L29 267 FILE BIOSIS
L30 179 FILE EMBASE
L31 612 FILE CAPLUS
L32 93 FILE WPIDS

TOTAL FOR ALL FILES

L33 1351 SHAN J?/AU

L34 372 FILE MEDLINE
L35 379 FILE BIOSIS
L36 372 FILE EMBASE
L37 492 FILE CAPLUS
L38 104 FILE WPIDS

TOTAL FOR ALL FILES

L39 1719 CHIU K?/AU

=> s l27 and l33 and l39

L40 1 FILE MEDLINE
L41 4 FILE BIOSIS
L42 1 FILE EMBASE
L43 2 FILE CAPLUS
L44 2 FILE WPIDS

TOTAL FOR ALL FILES

L45 10 L27 AND L33 AND L39

=> s l45 not l20

L46 1 FILE MEDLINE
L47 4 FILE BIOSIS
L48 1 FILE EMBASE
L49 1 FILE CAPLUS
L50 1 FILE WPIDS

TOTAL FOR ALL FILES

L51 8 L45 NOT L20

=> dup rem l51

PROCESSING COMPLETED FOR L51

L52 5 DUP REM L51 (3 DUPLICATES REMOVED)

=> d 1-5 ibib abs

L52 ANSWER 1 OF 5 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 2001:273191 BIOSIS

DOCUMENT NUMBER: PREV200100273191

TITLE: Chemical and pharmacological standardization of herbal ..
extracts.

AUTHOR(S): Pang, Peter K. T. [Inventor, Reprint author];
Shan, Jacqueline J. [Inventor]; Chiu, Kam
Wai [Inventor]

CORPORATE SOURCE: Sherwood Park, Canada
ASSIGNEE: CV Technologies Inc., Edmonton, Canada

PATENT INFORMATION: US 6156291 20001205

SOURCE: Official Gazette of the United States Patent and Trademark
Office Patents, (Dec. 5, 2000) Vol. 1241, No. 1. e-file.
CODEN: OGUPE7; ISSN: 0098-1133.

DOCUMENT TYPE: Patent

LANGUAGE: English

ENTRY DATE: Entered STN: 6 Jun 2001

Last Updated on STN: 19 Feb 2002

AB One of the aspects of the present invention relates to a method of
obtaining a reproducible extraction process for use as a standard process

for extracting a pharmacologically active mixture of chemical components from a plant, the method comprising: (a) extracting a plurality of pharmacologically active mixtures of chemical components from the plant in a plurality of different extraction processes to obtain a plurality of extracts; (b) obtaining a biological fingerprint of the pharmacological activity of each extract from step (a) by conducting at least two in vitro and at least two in vivo pharmacological tests on each extract, wherein each of the tests is known to correlate with effective treatment of a medical condition in a patient; (c) choosing one of the plurality of extracts which displays the best pharmacological activity in step (b); (d) repeating, at least once, the extraction process used to produce the chosen extract of step (c) to produce at least one test extract; (e) (1) obtaining chemical fingerprints of the chosen extract and the at least one test extract by distinguishing the identity and amount, relative to each other, of the chemical components in the pharmacologically active mixture of each extract, and (2) repeating said step (b) using the at least one test extract; and (f) comparing the chemical fingerprints and the biological fingerprints of the chosen extract and the at least one test extract.

L52 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 1999:172567 CAPLUS

DOCUMENT NUMBER: 130:200913

TITLE: Chemical and pharmacological standardization of herbal extracts

INVENTOR(S): Pang, Peter K. T.; Shan, Jacqueline J.; Chiu, Kam Wai

PATENT ASSIGNEE(S): CV Technologies Inc., Can.

SOURCE: PCT Int. Appl., 74 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9909837	A1	19990304	WO 1998-US17344	19980828
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6083932	A	20000704	US 1998-61961	19980417
CA 2301860	AA	19990304	CA 1998-2301860	19980828
AU 9890292	A1	19990316	AU 1998-90292	19980828
EP 1006802	A1	20000614	EP 1998-942181	19980828
R:	AT, CH, DE, FR, GB, IT, LI, FI			
US 6156291	A	20001205	US 1998-143361	19980828
JP 2001513533	T2	20010904	JP 2000-507241	19980828
PRIORITY APPLN. INFO.:			US 1997-56092P	P 19970828
			US 1997-44464P	P 19970418
			WO 1998-US17344	W 19980828
AB	A method for assuring the chemical and pharmacol. standardization of herbal exts. is disclosed. Chemical standardized herbal extract, CVT-E001. (a specific extract of Panax quinquefolium) with a characteristic chemical fingerprinting described was evaluated for its pharmacol. properties in improving memory			

in rats. CVT-E001 at a concentrate of about 1×10^{-6} saponins was always effective in promoting choline uptake and thus useful for treatment of cognitive and memory impairment conditions.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L52 ANSWER 3 OF 5 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
 ACCESSION NUMBER: 1997:186692 BIOSIS
 DOCUMENT NUMBER: PREV199799485895
 TITLE: Non-voltage dependent calcium channel and intracellular calcium regulation in rat vascular endothelial cells.
 AUTHOR(S): Pang, P. K. T.; Chiu, K. W.; Wu, X.; Shan, J.
 CORPORATE SOURCE: Dep. Physiol., Univ. Alberta, Edmonton, AB, Canada
 SOURCE: FASEB Journal, (1997) Vol. 11, No. 3, pp. A519.
 Meeting Info.: Annual Meeting of the Professional Research Scientists on Experimental Biology 97. New Orleans, Louisiana, USA. April 6-9, 1997.
 CODEN: FAJOEC. ISSN: 0892-6638.
 DOCUMENT TYPE: Conference; (Meeting)
 Conference; Abstract; (Meeting Abstract)
 LANGUAGE: English
 ENTRY DATE: Entered STN: 2 May 1997
 Last Updated on STN: 2 May 1997

L52 ANSWER 4 OF 5 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
 ACCESSION NUMBER: 1997:186596 BIOSIS
 DOCUMENT NUMBER: PREV199799485799
 TITLE: Effects of some herbal compounds on L and T calcium channel activities on vascular smooth muscle and neuroblastoma cells.
 AUTHOR(S): Chiu, K. W.; Shan, J.; Wu, X.; Pang, P. K. T.
 CORPORATE SOURCE: CV Technol. Inc., Edmonton, AB, Canada
 SOURCE: FASEB Journal, (1997) Vol. 11, No. 3, pp. A502.
 Meeting Info.: Annual Meeting of the Professional Research Scientists on Experimental Biology 97. New Orleans, Louisiana, USA. April 6-9, 1997.
 CODEN: FAJOEC. ISSN: 0892-6638.
 DOCUMENT TYPE: Conference; (Meeting)
 Conference; Abstract; (Meeting Abstract)
 LANGUAGE: English
 ENTRY DATE: Entered STN: 2 May 1997
 Last Updated on STN: 2 Jun 1997

L52 ANSWER 5 OF 5 MEDLINE on STN DUPLICATE 2
 ACCESSION NUMBER: 97082573 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 8923809
 TITLE: Tetramethylpyrazine, a calcium antagonist.
 AUTHOR: Pang P K; Shan J J; Chiu K W
 CORPORATE SOURCE: Department of Physiology, University of Alberta, Edmonton, Canada.
 SOURCE: Planta medica, (1996 Oct) Vol. 62, No. 5, pp. 431-5.
 Journal code: 0066751. ISSN: 0032-0943.
 PUB. COUNTRY: GERMANY: Germany, Federal Republic of
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 199701
 ENTRY DATE: Entered STN: 19970219

Last Updated on STN: 19970219

Entered Medline: 19970130

AB Tetramethylpyrazine (TMP) is a compound purified from a medicinal plant *Ligusticum wallichii* Franch. Its effects on in vivo blood pressure, in vitro vascular contractility, and intracellular calcium regulation in rats were examined in the present study to see if it was a possible calcium antagonist in the vascular tissue. Data showed that TMP was hypotensive and had a direct vascular effect. It not only blocked the entry of extracellular calcium through calcium channels but also inhibited the release of intracellular stored calcium in the vascular smooth muscle cell. It was a true calcium antagonist.

=> s (l27 or l33 or l39) and l8

L53 0 FILE MEDLINE
L54 1 FILE BIOSIS
L55 0 FILE EMBASE
L56 1 FILE CAPLUS
L57 1 FILE WPIDS

TOTAL FOR ALL FILES

L58 3 (L27 OR L33 OR L39) AND L8

=> s l58 not (l20 or l45)

L59 0 FILE MEDLINE
L60 1 FILE BIOSIS
L61 0 FILE EMBASE
L62 0 FILE CAPLUS
L63 0 FILE WPIDS

TOTAL FOR ALL FILES

L64 1 L58 NOT (L20 OR L45)

=> d ibib abs

L64 ANSWER 1 OF 1 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 2002:449637 BIOSIS

DOCUMENT NUMBER: PREV200200449637

TITLE: Problems in the use of herbal and natural substances, with a specific example concerning the cardiovascular system.

AUTHOR(S): Pang, Peter K. T. [Reprint author]; Benishin, Christina; Lewanczuk, Richard; Shan, Jacqueline

CORPORATE SOURCE: 9411 20th Avenue, Edmonton, AB, T6N 1E5, Canada
peter@cvtechnologies.com

SOURCE: Clinical and Experimental Pharmacology and Physiology, (August, 2002) Vol. 29, No. 8, pp. 731-734. print.
ISSN: 0305-1870.

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 21 Aug 2002

Last Updated on STN: 21 Aug 2002

AB 1. There has been increasing awareness and use of natural preparations for health purposes by consumers. 2. However, recent studies have repeatedly shown that many natural products marketed as nutraceuticals: or health food do not deliver the health benefit as claimed and are inconsistent from batch to batch. 3. The present paper describes the scientific rationale of such inconsistency and uses an antihypertensive preparation as an example to demonstrate the significant value of natural products if developed scientifically and properly.

=> s shark cartilage ext? or neovastat or ae-941 or (chondrichthyes or cartilagin? fish) (5a)ext?

L65 62 FILE MEDLINE
L66 93 FILE BIOSIS
L67 275 FILE EMBASE
L68 102 FILE CAPLUS
L69 46 FILE WPIDS

TOTAL FOR ALL FILES

L70 578 SHARK CARTILAGE EXT? OR NEOVASTAT OR AE-941 OR (CHONDRICHTHYES OR CARTILAGIN? FISH) (5A) EXT?

=> s l70(1)(antagonist or anti)

L71 12 FILE MEDLINE
L72 20 FILE BIOSIS
L73 13 FILE EMBASE
L74 21 FILE CAPLUS
L75 27 FILE WPIDS

TOTAL FOR ALL FILES

L76 93 L70(L) (ANTAGONIST OR ANTI)

=> s l76(1)(phf or parathyroid hypertens? factor)

L77 0 FILE MEDLINE
L78 0 FILE BIOSIS
L79 0 FILE EMBASE
L80 1 FILE CAPLUS
L81 1 FILE WPIDS

TOTAL FOR ALL FILES

L82 2 L76(L) (PHF OR PARATHYROID HYPERTENS? FACTOR)

=> dup rem l82

PROCESSING COMPLETED FOR L82

L83 1 DUP REM L82 (1 DUPLICATE REMOVED)

=> d

L83 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1

AN 1999:64822 CAPLUS

DN 130:90515

TI A preparation derived from shark cartilage for treatment of diseases related to excessive parathyroid hypertensive factor or excessive intracellular calcium

IN Pang, Peter K. T.; Shan, Jacqueline J.; Chiu, Kam W.

PA CV Technologies Inc., Can.

SO PCT Int. Appl., 30 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9902548	A1	19990121	WO 1998-US13591	19980709
	W:				
	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,				
	DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG,				
	KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,				
	NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,				

UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
 CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2295519	AA	19990121	CA 1998-2295519	19980709
AU 9883790	A1	19990208	AU 1998-83790	19980709
EP 1012163	A1	20000628	EP 1998-934212	19980709
R: AT, CH, DE, FR, GB, LI, FI				
JP 2001509513	T2	20010724	JP 2000-502067	19980709
US 2004234617	A1	20041125	US 2004-825661	20040416
PRAI US 1997-52233P	P	19970711		
WO 1998-US13591	W	19980709		
US 2000-462094	A1	20000111		

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s 170(1) (phf or parathyroid hypertens? factor)

L84	0	FILE MEDLINE
L85	1	FILE BIOSIS
L86	0	FILE EMBASE
L87	1	FILE CAPLUS
L88	1	FILE WPIDS

TOTAL FOR ALL FILES

L89	3	L70(L) (PHF OR PARATHYROID HYPERTENS? FACTOR)
-----	---	---

=> s 189 not 182

L90	0	FILE MEDLINE
L91	1	FILE BIOSIS
L92	0	FILE EMBASE
L93	0	FILE CAPLUS
L94	0	FILE WPIDS

TOTAL FOR ALL FILES

L95	1	L89 NOT L82
-----	---	-------------

=> d ibib abs

L95 ANSWER 1 OF 1 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
 ACCESSION NUMBER: 2002:449637 BIOSIS
 DOCUMENT NUMBER: PREV200200449637
 TITLE: Problems in the use of herbal and natural substances, with
 a specific example concerning the cardiovascular system.
 AUTHOR(S): Pang, Peter K. T. [Reprint author]; Benishin, Christina;
 Lewanczuk, Richard; Shan, Jacqueline
 CORPORATE SOURCE: 9411 20th Avenue, Edmonton, AB, T6N 1E5, Canada
 peter@cvtechnologies.com
 SOURCE: Clinical and Experimental Pharmacology and Physiology,
 (August, 2002) Vol. 29, No. 8, pp. 731-734. print.
 ISSN: 0305-1870.
 DOCUMENT TYPE: Article
 LANGUAGE: English
 ENTRY DATE: Entered STN: 21 Aug 2002
 Last Updated on STN: 21 Aug 2002
 AB 1. There has been increasing awareness and use of natural preparations
 for health purposes by consumers. 2. However, recent studies have
 repeatedly shown that many natural products marketed as nutraceuticals: or
 health food do not deliver the health benefit as claimed and are

inconsistent from batch to batch. 3. The present paper describes the scientific rationale of such inconsistency and uses an antihypertensive preparation as an example to demonstrate the significant value of natural products if developed scientifically and properly.

=> s extract? and (clean? or dried or ground) and (shark cartilage or neovastat or ae-941 or ae 941) and water and centrifug?

L96 0 FILE MEDLINE
L97 0 FILE BIOSIS
L98 0 FILE EMBASE
L99 0 FILE CAPLUS
L100 0 FILE WPIDS

TOTAL FOR ALL FILES

L101 0 EXTRACT? AND (CLEAN? OR DRIED OR GROUND) AND (SHARK CARTILAGE OR NEOVASTAT OR AE-941 OR AE 941) AND WATER AND CENTRIFUG?

=> fil aquasci

COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
225.31	236.22

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE ENTRY	TOTAL SESSION
-1.50	-1.50

CA SUBSCRIBER PRICE

FILE 'AQUASCI' ENTERED AT 14:49:05 ON 27 FEB 2006

COPYRIGHT 2006 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE COVERS 1978 TO 15 Feb 2006 (20060215/ED)

=> s l101

28440 EXTRACT?
9312 CLEAN?
4181 DRIED
17233 GROUND
12763 GROUNDS
28576 GROUND
(GROUND OR GROUNDS)
3858 "SHARK"
2666 "SHARKS"
4985 "SHARK"
("SHARK" OR "SHARKS")
632 "CARTILAGE"
139 "CARTILAGES"
701 "CARTILAGE"
("CARTILAGE" OR "CARTILAGES")
35 SHARK CARTILAGE
("SHARK" (W) "CARTILAGE")
1 NEOVASTAT
1360 "AE"
308 "AES"
1611 "AE"
("AE" OR "AES")
59 "941"
1 AE-941
("AE" (W) "941")
1360 "AE"
308 "AES"

```

1611 "AE"
      ("AE" OR "AES")
59 "941"
1 AE 941
      ("AE" (W) "941")
288987 WATER
94272 WATERS
336050 WATER
      (WATER OR WATERS)
2446 CENTRIFUG?
L102 0 EXTRACT? AND (CLEAN? OR DRIED OR GROUND) AND (SHARK CARTILAGE
      OR NEOVASTAT OR AE-941 OR AE 941) AND WATER AND CENTRIFUG?

=> s shark cartilage ext? or neovastat or ae-941 or (chondrichthyes or cartilagin?
fish) (5a)ext?
3858 "SHARK"
2666 "SHARKS"
4985 "SHARK"
      ("SHARK" OR "SHARKS")
632 "CARTILAGE"
139 "CARTILAGES"
701 "CARTILAGE"
      ("CARTILAGE" OR "CARTILAGES")
152065 EXT?
5 SHARK CARTILAGE EXT?
      ("SHARK" (W) "CARTILAGE" (W) EXT?)
1 NEOVASTAT
1360 "AE"
308 "AES"
1611 "AE"
      ("AE" OR "AES")
59 "941"
1 AE-941
      ("AE" (W) "941")
723 CHONDRICHTHYES
692 CARTILAGIN?
218321 "FISH"
37813 "FISHES"
229744 "FISH"
      ("FISH" OR "FISHES")
372 CARTILAGIN? FISH
      (CARTILAGIN? (W) "FISH")
152065 EXT?
7 (CHONDRICHTHYES OR CARTILAGIN? FISH) (5A)EXT?
L103 12 SHARK CARTILAGE EXT? OR NEOVASTAT OR AE-941 OR (CHONDRICHTHYES
      OR CARTILAGIN? FISH) (5A)EXT?

=> s l103(1) (phf or parathyroid hypertens? factor)
5 PHF
82 "PARATHYROID"
4 "PARATHYROIDS"
82 "PARATHYROID"
      ("PARATHYROID" OR "PARATHYROIDS")
97 HYPERTENS?
30201 "FACTOR"
70461 "FACTORS"
93916 "FACTOR"
      ("FACTOR" OR "FACTORS")
0 PARATHYROID HYPERTENS? FACTOR
      ("PARATHYROID" (W) HYPERTENS? (W) "FACTOR")

```

L104 0 L103(L) (PHF OR PARATHYROID HYPERTENS? FACTOR)

=> d 1-12 l103

L103 ANSWER 1 OF 12 AQUASCI COPYRIGHT 2006 FAO (On behalf of the ASFA Advisory Board). All rights reserved. on STN

AN 2005:37635 AQUASCI

DN ASFA1 2005

TI Placoderm fishes, pharyngeal denticles, and the vertebrate dentition

AU Johanson, Z.; Smith, M.M.

CS Palaeontology, Australian Museum, 6 College Street, Sydney, NSW 2010, Australia; E-mail: zerinaj@austmus.gov.au

SO Journal of Morphology [J. Morphol.], (20030900) vol. 257, no. 3, pp. 289-307.

ISSN: 0362-2525.

DT Journal

FS ASFA1

LA English

SL English

L103 ANSWER 2 OF 12 AQUASCI COPYRIGHT 2006 FAO (On behalf of the ASFA Advisory Board). All rights reserved. on STN

AN 2003:41273 AQUASCI

DN ASFA1 2003 33-13946

TI Sharks: A Potential Source of Antiangiogenic Factors and Tumor Treatments

AU Cho, J.J.; Kim, Y.T.*

CS Department of Microbiology, Pukyong National University, Pusan 608-737, Korea; E-mail: ytkim@pknu.ac.kr

SO Marine Biotechnology [Mar. Biotechnol.], (20020000) vol. 4, no. 6, pp. 521-525.

ISSN: 1436-2228.

DT Journal

TC General Review

FS ASFA1

LA English

SL English

L103 ANSWER 3 OF 12 AQUASCI COPYRIGHT 2006 FAO (On behalf of the ASFA Advisory Board). All rights reserved. on STN

AN 2001:44295 AQUASCI

DN ASFA1 2001

TI Extracts of shark cartilage having anti-collagenolytic, anti-inflammatory, anti-angiogenic and anti-tumoral activities; process of making, methods of using and compositions thereof

AU Dupont, E.; Brazeau, P.; Juneau, C.; Maes, D.; Marenus, K.

CS Les Laboratoires Aeterna Inc.

PI US 6025334

SO (2000021) . US CLASS: 514/21; 514/828; 514/855; 514/859; 514/863; 514/886; 514/887; 530/400; 530/412; 530/414; 530/415; 530/417; 530/418; 530/427.

DT Patent

FS ASFA1

LA English

SL English

L103 ANSWER 4 OF 12 AQUASCI COPYRIGHT 2006 FAO (On behalf of the ASFA Advisory Board). All rights reserved. on STN

AN 2000:24643 AQUASCI

DN ASFA1 2000 30-16737

TI Distribution of Choline Acetyltransferase Immunoreactivity in the Brain of an Elasmobranch, the Lesser Spotted Dogfish (Scyliorhinus canicula)

AU Anadon, R.; Molist, P.; Rodriguez-Moldes, I.; Lopez, J.M.; Quintela, I.; Cervino, M.C.; Barja, P.; Gonzalez, A.
CS Department of Fundamental Biology, University of Santiago de Compostela, 15706-Santiago de Compostela, Spain); E-mail: bfanadon@usc.e
SO Journal of Comparative Neurology [J. Comp. Neurol.], (20000501) vol. 420, no. 2, pp. 139-170.
ISSN: 0021-9967.
DT Journal
FS ASFA1
LA English
SL English

L103 ANSWER 5 OF 12 AQUASCI COPYRIGHT 2006 FAO (On behalf of the ASFA Advisory Board). All rights reserved. on STN
AN 2000:20211 AQUASCI
DN ASFA1 2000
TI Extracts of shark cartilage having an anti-angiogenic activity and an effect on tumor regression: process of making thereof
AU Dupont, E.; Brazeau, P.; Juneau, C.
CS Les Laboratoires Aeterna Inc.
PI US 5985839
SO (19991116) . US CLASS: 514/21; 514/828; 514/855; 514/859; 514/863; 514/886; 514/887; 530/400; 530/412; 530/414; 530/415; 530/417; 530/418; 530/427..
DT Patent
FS ASFA1
LA English
SL English

L103 ANSWER 6 OF 12 AQUASCI COPYRIGHT 2006 FAO (On behalf of the ASFA Advisory Board). All rights reserved. on STN
AN 2000:20210 AQUASCI
DN ASFA1 2000
TI Methods of using extracts of shark cartilage
AU Dupont, E.; Brazeau, P.; Juneau, C.; Maes, D.; Marenus, K.
CS Les Laboratoires Aeterna Inc.
PI US 6028118
SO (20000222) . US CLASS: 514/863; 514/859; 514/828; 424/520..
DT Patent
FS ASFA1
LA English
SL English

L103 ANSWER 7 OF 12 AQUASCI COPYRIGHT 2006 FAO (On behalf of the ASFA Advisory Board). All rights reserved. on STN
AN 1999:51836 AQUASCI
DN ASFA1 1999
TI Visual Thalamotelencephalic Pathways in the Sturgeon Acipenser, a Non-Teleost Actinopterygian Fish
AU Albert, J.S.; Yamamoto, Naoyuki; Yoshimoto, Masami; Sawai, Nobuhiko; Ito, Hironobu
CS Nippon Medical School, Department of Anatomy, Sendagi 1-1-5, Bunkyo-ku, Tokyo 113-8602, Japan); E-mail: albert@nms.ac.j
SO Brain, Behavior and Evolution [Brain Behav. Evol.], (19990000) vol. 53, no. 3, pp. 156-172.
ISSN: 0006-8977.
DT Journal
FS ASFA1
LA English
SL English

- L103 ANSWER 8 OF 12 AQUASCI COPYRIGHT 2006 FAO (On behalf of the ASFA Advisory Board). All rights reserved. on STN
AN 1999:39524 AQUASCI
DN ASFA1 1999
TI Purification and primary structure of pituitary adenylate cyclase activating polypeptide (PACAP) from the brain of an elasmobranch, stingray, *Dasyatis akajei*
AU Matsuda, K.; Yoshida, T.; Nagano, Y.; Kashimoto, K.; Yatohgo, T.; Shimomura, H.; Shioda, S.; Arimura, A.; Uchiyama, M.
CS Department of Biology, Faculty of Science, Toyama University, Gofuku, Toyama 930-8555, Japan); E-mail: kmatsuda@sci.toyama-u.ac.j
SO Peptides, (19980000) vol. 19, no. 9, pp. 1489-1495.
ISSN: 0196-9781.
DT Journal
FS ASFA1
LA English
SL English
- L103 ANSWER 9 OF 12 AQUASCI COPYRIGHT 2006 FAO (On behalf of the ASFA Advisory Board). All rights reserved. on STN
AN 1999:30606 AQUASCI
DN ASFA1 1999
TI Antibodies of sharks: revolution and evolution
AU Marchalonis, J.J.; Schluter, S.F.; Bernstein, R.M.; Hohman, V.S.
CS Department of Microbiology and Immunology, P. O. Box 24-5049, University of Arizona, Tucson AZ 85724, USA); E-mail: dianah@u.arizona.ed
SO Immunological Reviews [Immunol. Rev.], (19981200) vol. 166, pp. 103-122.
Immune systems of ectothermic vertebrates..
ISSN: 0105-2896.
DT Journal
TC General Review
FS ASFA1
LA English
SL English
- L103 ANSWER 10 OF 12 AQUASCI COPYRIGHT 2006 FAO (On behalf of the ASFA Advisory Board). All rights reserved. on STN
AN 1999:30516 AQUASCI
DN ASFA1 1999
TI Extracts of shark cartilage having an anti-angiogenic activity and an effect on tumor regression; process of making thereof
AU Dupont, E.; Brazeau, P.; Juneau, C.
CS Les Laboratoires Aeterna Inc.
PI US 5618925
SO (19970408) . US Class: 530/400; 530/350; 530/412; 530/414; 530/415; 530/417; 530/418; 530/427..
DT Patent
FS ASFA1
LA English
SL English
- L103 ANSWER 11 OF 12 AQUASCI COPYRIGHT 2006 FAO (On behalf of the ASFA Advisory Board). All rights reserved. on STN
AN 1998:27078 AQUASCI
DN ASFA1 1998 28-12160
TI Coevolution of the Monogenoidea (Platyhelminthes) based on a revised hypothesis of parasite phylogeny
AU Boeger, W.A.; Kritsky, D.C.*
CS Coll. Health Professions, Campus Box 8090, Idaho State Univ., Pocatello,

ID 83209, USA
SO INT. J. PARASITOL., (1997) 27, no. 12, pp. 1495-1511.
ISSN: 0020-7519.
DT Journal
FS ASFA1
LA English
SL English

L103 ANSWER 12 OF 12 AQUASCI COPYRIGHT 2006 FAO (On behalf of the ASFA
Advisory Board). All rights reserved. on STN
AN 89:16455 AQUASCI
DN ASFA1 1990 20-21442
TI Reproduction and development of chondrichthyan fishes.
BIOLOGY OF SELACHIANS: SEMINAR 2 DECEMBER 1988.
Reproduction et developpement des chondrichthyens
BIOLOGIE DES SELACIENS, 2 DECEMBRE 1988.
AU Mellinger, J.
CS Lab. Biol. Anim., Fac. Sci., Univ. Reims, B.P. 347, 51062 Reims Cedex,
France; Institut Oceanographique, Paris (France)
SO OCEANIS (DOC. OCEANOGR.), (1989) pp. 283-308.
Meeting Info.: Biology des Selaciens. Paris (France). 2 Dec 1988.
ISSN: 0182-0745.
DT Book
TC Conference
FS ASFA1
LA French
SL English; French

=> dis his

(FILE 'HOME' ENTERED AT 14:23:56 ON 27 FEB 2006)

FILE 'CAPLUS' ENTERED AT 14:33:37 ON 27 FEB 2006
E SHARK CARTILAGE/CT

FILE 'AQUASCI' ENTERED AT 14:34:04 ON 27 FEB 2006
E SHARK CARTILAGE/CT

FILE 'EMBASE' ENTERED AT 14:34:24 ON 27 FEB 2006
E SHARK CARTILAGE/CT

L1 5 S E3
E E3+ALL
L2 17 S E3-E34

FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS, WPIDS' ENTERED AT 14:35:33 ON 27
FEB 2006

L3 43 FILE MEDLINE
L4 36 FILE BIOSIS
L5 25 FILE EMBASE
L6 34 FILE CAPLUS
L7 23 FILE WPIDS
TOTAL FOR ALL FILES
L8 161 S L2 OR SHARK CARTILAGE EXT?
L9 0 FILE MEDLINE
L10 0 FILE BIOSIS
L11 0 FILE EMBASE
L12 0 FILE CAPLUS
L13 0 FILE WPIDS
TOTAL FOR ALL FILES

L14	0 S L8 AND ANTI PHF
L15	0 FILE MEDLINE
L16	0 FILE BIOSIS
L17	0 FILE EMBASE
L18	1 FILE CAPLUS
L19	1 FILE WPIDS
TOTAL FOR ALL FILES	
L20	2 S PHF AND L8
L21	1 DUP REM L20 (1 DUPLICATE REMOVED)
L22	315 FILE MEDLINE
L23	470 FILE BIOSIS
L24	303 FILE EMBASE
L25	451 FILE CAPLUS
L26	48 FILE WPIDS
TOTAL FOR ALL FILES	
L27	1587 S PANG P?/AU
L28	200 FILE MEDLINE
L29	267 FILE BIOSIS
L30	179 FILE EMBASE
L31	612 FILE CAPLUS
L32	93 FILE WPIDS
TOTAL FOR ALL FILES	
L33	1351 S SHAN J?/AU
L34	372 FILE MEDLINE
L35	379 FILE BIOSIS
L36	372 FILE EMBASE
L37	492 FILE CAPLUS
L38	104 FILE WPIDS
TOTAL FOR ALL FILES	
L39	1719 S CHIU K?/AU
L40	1 FILE MEDLINE
L41	4 FILE BIOSIS
L42	1 FILE EMBASE
L43	2 FILE CAPLUS
L44	2 FILE WPIDS
TOTAL FOR ALL FILES	
L45	10 S L27 AND L33 AND L39
L46	1 FILE MEDLINE
L47	4 FILE BIOSIS
L48	1 FILE EMBASE
L49	1 FILE CAPLUS
L50	1 FILE WPIDS
TOTAL FOR ALL FILES	
L51	8 S L45 NOT L20
L52	5 DUP REM L51 (3 DUPLICATES REMOVED)
L53	0 FILE MEDLINE
L54	1 FILE BIOSIS
L55	0 FILE EMBASE
L56	1 FILE CAPLUS
L57	1 FILE WPIDS
TOTAL FOR ALL FILES	
L58	3 S (L27 OR L33 OR L39) AND L8
L59	0 FILE MEDLINE
L60	1 FILE BIOSIS
L61	0 FILE EMBASE
L62	0 FILE CAPLUS
L63	0 FILE WPIDS
TOTAL FOR ALL FILES	
L64	1 S L58 NOT (L20 OR L45)
L65	62 FILE MEDLINE

```

L66          93 FILE BIOSIS
L67          275 FILE EMBASE
L68          102 FILE CAPLUS
L69          46 FILE WPIDS
TOTAL FOR ALL FILES
L70          578 S SHARK CARTILAGE EXT? OR NEOVASTAT OR AE-941 OR (CHONDRICHTHYE
L71          12 FILE MEDLINE
L72          20 FILE BIOSIS
L73          13 FILE EMBASE
L74          21 FILE CAPLUS
L75          27 FILE WPIDS
TOTAL FOR ALL FILES
L76          93 S L70 (L) (ANTAGONIST OR ANTI)
L77          0 FILE MEDLINE
L78          0 FILE BIOSIS
L79          0 FILE EMBASE
L80          1 FILE CAPLUS
L81          1 FILE WPIDS
TOTAL FOR ALL FILES
L82          2 S L76 (L) (PHF OR PARATHYROID HYPERTENS? FACTOR)
L83          1 DUP REM L82 (1 DUPLICATE REMOVED)
L84          0 FILE MEDLINE
L85          1 FILE BIOSIS
L86          0 FILE EMBASE
L87          1 FILE CAPLUS
L88          1 FILE WPIDS
TOTAL FOR ALL FILES
L89          3 S L70 (L) (PHF OR PARATHYROID HYPERTENS? FACTOR)
L90          0 FILE MEDLINE
L91          1 FILE BIOSIS
L92          0 FILE EMBASE
L93          0 FILE CAPLUS
L94          0 FILE WPIDS
TOTAL FOR ALL FILES
L95          1 S L89 NOT L82
L96          0 FILE MEDLINE
L97          0 FILE BIOSIS
L98          0 FILE EMBASE
L99          0 FILE CAPLUS
L100         0 FILE WPIDS
TOTAL FOR ALL FILES
L101         0 S EXTRACT? AND (CLEAN? OR DRIED OR GROUND) AND (SHARK CARTILAGE
FILE 'AQUASCI' ENTERED AT 14:49:05 ON 27 FEB 2006
L102         0 S L101
L103         12 S SHARK CARTILAGE EXT? OR NEOVASTAT OR AE-941 OR (CHONDRICHTHYE
L104         0 S L103 (L) (PHF OR PARATHYROID HYPERTENS? FACTOR)

```

```

=> s l27 and l33 and l39
      100 PANG P?/AU
      16 SHAN J?/AU
      11 CHIU K?/AU
L105      0 L27 AND L33 AND L39

```

```

=> log y
COST IN U.S. DOLLARS          SINCE FILE          TOTAL
                                ENTRY          SESSION
FULL ESTIMATED COST          21.46          257.68

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)  SINCE FILE          TOTAL

```

Page 17

	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-1.50

STN INTERNATIONAL LOGOFF AT 14:50:27 ON 27 FEB 2006